Peptron announced on the 15th that its prostate cancer and precocious puberty treatment 'Loopone' has received marketing authorization from the Ministry of Food and Drug Safety. This is a one-month sustained release treatment that remains effective for one month with a single administration.
Loopone is a generic medicine of the original drug Lupron (active ingredient leuprolide) developed by Japan's Takeda Pharmaceutical, and it is the first drug developed using Peptron's long-acting treatment platform.
Leuprolide formulations inhibit the production of male hormones, thereby suppressing the growth of prostate cancer cells and providing treatment for precocious puberty.
The company explained that Loopone is the only generic leuprolide formulation currently on the domestic market that has proven biological equivalence (BE) to the original drug through clinical trials. Additionally, it is the first drug to meet the pharmacokinetic (PK) equivalence standards of developed countries outside of Japan.
Loopone is the first commercially produced product manufactured by Peptron. According to the exclusive domestic sales agreement signed with LG CHEM, Peptron will handle manufacturing while LG CHEM will be responsible for domestic sales.
The company stated, "Both companies will aggressively target the domestic prostate cancer and precocious puberty treatment market, estimated to be worth about 800 billion won," adding that the Osong Bio Park factory has also completed preparations for the production of Loopone.